Tocilizumab shortage raises questions about alternatives for GCA and JIA

Pharma giant Roche has repeated assurances that it is going all out to ramp up global production of tocilizumab (Actemra) to cover arthritis patients in therapy as well as supply growing numbers of severely ill COVID-19 patients around the world. Roche Australia earlier this month notified the TGA and rheumatologists that three formulations of tocilizumab ...

Already a member?

Login to keep reading.

© 2021 the limbic